Vasella to leave Novartis in August


Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company.

He will not seek re-election in February, paving the way for a new chair from 1 August. His successor will be Jörg Reinhardt, who is currently running the drug division at Bayer. Vice chair Ulrich Lehner will serve in the interim.

Vasella was chief executive from 1996 to 2010 and became chair in 1999. His resignation as chief executive in 2010 came after a string of attacks by militant animal rights activists aimed at him and his family. The incoming chair, Reinhardt, is a scientist by training, with a PhD in pharmaceutical sciences, who climbed the R&D ranks at Sandoz before the merger with Ciba-Geigy that created Novartis. He arrives at a challenging time for Novartis, which is struggling with the expiry of patents for many of its financially important drugs.


Related Content

Business roundup

26 February 2010 Business

news image

Industry news, March 2010

Business roundup

25 August 2009 Business

news image

Industry news, September 2009

Most Commented

How to print a crystal in 3D

17 April 2014 Research

news image

Rather than looking at a crystal on a screen, print it out and hold it in your hand

The sultan of synthesis

11 April 2014 Feature

news image

Phil Baran is spurring organic chemists to rethink how they make complex compounds, as Mark Peplow discovers